Patents Assigned to Inserm
  • Hepcidin inhibitors for regulating iron homeostasis
    Patent number: 9234903
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anemia.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: January 12, 2016
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Gaël Nicolas, Sophie Vaulont, Axel Kahn
  • METHOD FOR CLASSIFYING AN INFLAMMATORY BOWEL DISEASE AS A CROHN'S DISEASE OR AS AN ULCERATIVE COLITIS
    Publication number: 20160002730
    Abstract: The present invention relates to a method for classifying an inflammatory bowel disease in a patient as a Crohn's disease or as an ulcerative colitis, said method comprising a step of measuring an expression profile of miRNA in a sample from the patient, wherein said miRNA are miR15a, miR26a, miR29a, miR29b, miR30c, miR126*, miR127-3p, miR-142-3p, miR-142-5p, miR-146a, miR-146b-5p, miR150, miR-181d, miR-182, miR185, miR196a, miR199a-3p, miR199a-5p, miR199b-5p, miR-203, miR223, miR-299-5p, miR320a, miR324-3p, miR-328.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric OGIER-DENIS, Xavier TRETON
  • Drug monitoring methods using the promyelocytic leukemia protein as a redox sensor
    Patent number: 9228998
    Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: January 5, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Hugues De The, Valerie Lallemand-Breitenbach
  • USE OF CD31 PEPTIDES IN THE TREATMENT OF THROMBOTIC AND AUTOIMMUNE DISORDERS
    Publication number: 20150376258
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.
    Type: Application
    Filed: July 27, 2015
    Publication date: December 31, 2015
    Applicant: INSERM (Institute National de la Sante et de la Recherche Medicale
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS
    Publication number: 20150377892
    Abstract: The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperon activity and/or is not capable of binding to best-shock protein 70 (HSP70) and/or to beat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat-shock protein 110 can be used (i) in methods for proposing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm), UNIVERSITE DE BOURGOGNE
    Inventors: Carmen GARRIDO, Alex DUVAL
  • METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER
    Publication number: 20150369811
    Abstract: The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.
    Type: Application
    Filed: August 27, 2015
    Publication date: December 24, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes - Paris V, Assistance Publique - Hopitaux de Paris
    Inventors: Jerome GALON, Franck PAGES, Herve FRIDMAN, Bernhard MLECNIK
  • DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE
    Publication number: 20150368715
    Abstract: The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure.
    Type: Application
    Filed: June 25, 2015
    Publication date: December 24, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Fatima SMIH, Philippe ROUET
  • Non human animal model for ulcerative colitis and its main complications
    Patent number: 9217156
    Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Ogier-Denis, Xavier Treton, Fanny Daniel, Cecile Guichard, Eric Pedruzzi, Yoram Bouhnik, Yann Harnoy
  • Combination of a statin and a taxane for the treatment of gastric cancer
    Patent number: 9216165
    Abstract: The present invention relates to a combination of (i) a statin, and (ii) a taxane, for simultaneous or sequential use in the treatment of a patient suffering from solid tumor, e.g. a gastric cancer. The present invention also provides a statin, for use in a method for enhancing sensitivity of a patient suffering from a solid tumor to a taxane.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 22, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Bretagne Occidentale
    Inventors: Laurent Corcos, Catherine Le Jossic-Corcos
  • Virosome-like vesicles comprising gp41-derived antigens
    Patent number: 9216156
    Abstract: The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: December 22, 2015
    Assignees: MYMETICS CORPORATION, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), PEVION BIOTECH LTD.
    Inventors: Sylvain Fleury, Morgane Bomsel, Rinaldo Zurbriggen
  • Methods and pharmaceutical compositions for the treatment of hypertension
    Patent number: 9212361
    Abstract: The present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing hypertension in a subject in need thereof.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: December 15, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot (Paris VII), Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus
  • ANTI-CD277 ANTIBODIES AND USES THEREOF
    Publication number: 20150353643
    Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
    Type: Application
    Filed: July 6, 2015
    Publication date: December 10, 2015
    Applicants: UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille II, INSTITUT PAOLI-CALMETTES, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
  • Methods and Pharmaceutical Composition for the Preservation of Vascular Endothelial Cell Barrier Integrity
    Publication number: 20150353618
    Abstract: The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 10, 2015
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Stephane Germain, Galaup Ariane, Catherine Monnot, Renaud Tissier, Bijan Ghaleh, Alain Berdeaux
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES
    Publication number: 20150342876
    Abstract: The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 3, 2015
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITÉ PARIS DESCARTES
    Inventors: Francine BEHAR-COHEN, Elodie BOUSQUET
  • Method and pharmaceutical composition for use in the treatment of cancer
    Patent number: 9198949
    Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 1, 2015
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE UPMC, UNIVERSITE PARIS DIDEROT-PARIS 7, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
  • Use of FSH receptor ligands for diagnosis and therapy of cancer
    Patent number: 9200076
    Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: December 1, 2015
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Nicolae Ghinea, Aurelian Radu
  • Methods for the treatment of nonalcoholic steatohepatitis
    Patent number: 9193971
    Abstract: The present invention relates to the treatment of nonalcoholic steatohepatitis (NASH), in particular to a compound that inhibits miR-21 expression for use in the treatment of nonalcoholic steatohepatitis.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: November 24, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes
    Inventors: Alain Tedgui, Xavier Loyer, Pierre-Emmanuel Rautou
  • MITF as a marker for predisposition to cancer
    Patent number: 9194003
    Abstract: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 24, 2015
    Assignees: INSTITUT GUSTAVE ROUSSY, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE SOPHIA NICE ANTIPOLIS
    Inventors: Robert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur
  • Apoptosis inducing compounds
    Patent number: 9193699
    Abstract: Provided are compounds of formula (I): wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human cancers.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: November 24, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITÉ D'AIX-MARSEILLE, L'INSTITUT PAOLI-CALMETTES
    Inventors: Marc Lopez, Yves Collette, Lynda Mezil, Jean-Michel Brunel, Sebastien Combes
  • POROUS POLYSACCHARIDE SCAFFOLD COMPRISING NANO-HYDROXYAPATITE AND USE FOR BONE FORMATION
    Publication number: 20150328365
    Abstract: The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stent cells or growth factors.
    Type: Application
    Filed: June 2, 2015
    Publication date: November 19, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Bordeaux II Victor Segalen, Universite Paris Diderot - Paris 7
    Inventors: Joelle AMEDEE, Didier LETOURNEUR, Catherine LE VISAGE, Sidi Mohammed DERKAOUI, Jean-Christophe FRICAIN, Sylvain CATROS